| Goepfert, Paul |
NCT04101838: B Cell and Antibody Response to Seasonal Influenza Vaccines in Younger and Older Adults |
|
|
| Recruiting | 4 | 50 | US | Fluzone, influenza vaccine, Flucelvax, Fluzone High-Dose, high dose influenza vaccine, Fluad, adjuvanted influenza vaccine | University of Alabama at Birmingham | Influenza | 05/25 | 05/25 | | |
| Recruiting | 3 | 2000 | US | BCG (Tokyo 172) vaccine, Placebo, sodium glutamate | Henry M. Jackson Foundation for the Advancement of Military Medicine, United States Department of Defense, Uniformed Services University of the Health Sciences | Tuberculosis Infection | 09/27 | 09/27 | | |
NCT05854381: To Investigate Safety, Reactogenicity and Immunogenicity of VIR-1388 Compared With Placebo in Participants Without HIV |
|
|
| Active, not recruiting | 1 | 95 | US, RoW | VIR-1388, Placebo | Vir Biotechnology, Inc., National Institute of Allergy and Infectious Diseases (NIAID), HIV Vaccine Trials Network | HIV I Infection | 11/25 | 11/27 | | |
| Overton, Edgar Turner |
| Recruiting | 3 | 2000 | US | BCG (Tokyo 172) vaccine, Placebo, sodium glutamate | Henry M. Jackson Foundation for the Advancement of Military Medicine, United States Department of Defense, Uniformed Services University of the Health Sciences | Tuberculosis Infection | 09/27 | 09/27 | | |
NCT05023044: Nonalcoholic Fatty Liver Disease in HIV Database |
|
|
| Recruiting | N/A | 400 | US | | Johns Hopkins University, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | NAFLD, NASH - Nonalcoholic Steatohepatitis, Hiv | 01/26 | 01/26 | | |
| Heath, Sonya |
NCT04636437: Doravirine for Persons With Excessive Weight Gain on Integrase Inhibitors and Tenofovir Alafenamide |
|
|
| Active, not recruiting | 4 | 222 | US | Doravirine 100 Mg, Tenofovir alafenamide/emtricitabine, tenofovir alafenamide/lamivudine, Integrase strand transfer inhibitors, tenofovir disproxil fumarate/emtricitabine, tenofovir disproxil fumarate/lamivudine | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections | 11/24 | 11/24 | | |
| Active, not recruiting | 3 | 719 | Japan, US, RoW | Tecovirimat Oral Capsule, Placebo, Tecovirimat Oral Capsule (Open Label) | National Institute of Allergy and Infectious Diseases (NIAID), SIGA Technologies | MPOX | 10/24 | 09/25 | | |
| Recruiting | 3 | 2000 | US | BCG (Tokyo 172) vaccine, Placebo, sodium glutamate | Henry M. Jackson Foundation for the Advancement of Military Medicine, United States Department of Defense, Uniformed Services University of the Health Sciences | Tuberculosis Infection | 09/27 | 09/27 | | |
VOLITION, NCT05917509: A Study to Evaluate the Efficacy, Safety, Participant Choice and Preference of an Oral Once-daily Regimen or a Long-acting Injectable Regimen Every Two Months for Treatment of Human Immunodeficiency Virus (HIV-1) in Adults Who Have Not Previously Taken Antiretroviral Therapy |
|
|
| Active, not recruiting | 3 | 171 | Europe, Canada, US, RoW | DTG/3TC, Dovato, Cabotegravir (CAB) LA, Vocabria, Rilpivirine (RPV) LA, Rekambys | ViiV Healthcare, GlaxoSmithKline, PPD DEVELOPMENT, LP | HIV Infections | 10/25 | 10/26 | | |
EMBRACE, NCT05996471: A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV) |
|
|
| Active, not recruiting | 2 | 128 | US | VH3810109, Cabotegravir, Standard of care (SOC), rHuPH20 | ViiV Healthcare | HIV Infections | 11/24 | 05/26 | | |
NCT05903339: Clinical Trial to Evaluate the Safety and Immunogenicity of Ferritin Nanoparticles Expressing Native-like HIV-1 Envelope Trimers Followed by Boost With mRNA Lipid Nanoparticles Encoding a Native-like HIV-1 Envelope Trimer in Adults Without HIV |
|
|
| Active, not recruiting | 1 | 36 | US | V3G CH848 Pr-NP1 60mcg, 3M-052-AF 5mcg, Alum 500 mcg, V3G CH848 mRNA-Tr2 50mcg, ACU-026-001-1 2.0mg, V3G CH848 Pr-NP1 100mcg | National Institute of Allergy and Infectious Diseases (NIAID) | Hiv | 08/25 | 08/25 | | |
NCT04795219: Prevalence and Predictors of Hepatic Steatosis in Persons Living With HIV |
|
|
| Recruiting | N/A | 1250 | US | | University of California, San Francisco, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | NAFLD, NAFLD-HIV, Hiv | 01/25 | 01/25 | | |
NCT05023044: Nonalcoholic Fatty Liver Disease in HIV Database |
|
|
| Recruiting | N/A | 400 | US | | Johns Hopkins University, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | NAFLD, NASH - Nonalcoholic Steatohepatitis, Hiv | 01/26 | 01/26 | | |
| Johnson, Catrena |
| Recruiting | 3 | 2000 | US | BCG (Tokyo 172) vaccine, Placebo, sodium glutamate | Henry M. Jackson Foundation for the Advancement of Military Medicine, United States Department of Defense, Uniformed Services University of the Health Sciences | Tuberculosis Infection | 09/27 | 09/27 | | |
| Logan, Heather |
| Recruiting | 3 | 2000 | US | BCG (Tokyo 172) vaccine, Placebo, sodium glutamate | Henry M. Jackson Foundation for the Advancement of Military Medicine, United States Department of Defense, Uniformed Services University of the Health Sciences | Tuberculosis Infection | 09/27 | 09/27 | | |
NCT06560684: CROSSOVER STUDY OF ON-DEMAND PREP FORMULATIONS COMPARING RECTAL AND ORAL TENOFOVIR |
|
|
| Recruiting | 2 | 150 | US | Oral F/TDF Pills, TFV rectal douche | National Institute of Allergy and Infectious Diseases (NIAID) | Tenofovir | 01/26 | 01/26 | | |
NCT06705478: Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV |
|
|
| Not yet recruiting | 2 | 186 | US, RoW | Pramipexole ER, Escitalopram | National Institute of Allergy and Infectious Diseases (NIAID), Cipla Ltd. | Major Depressive Disorder, Mild Neurocognitive Disorder, HIV | 12/26 | 12/26 | | |
NCT06332339: Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 16055 NFL Delta Gly4 Env Protein Trimer and Trimer 4571 Combined With 3M-052-AF + Alum Adjuvant and Ad4-Env145NFL Viral Particles as Heterologous Prime-boost Regimens in Adult Participants Without HIV. |
|
|
| Active, not recruiting | 1 | 45 | US | 16055 NFL delta Gly4 trimer, Trimer 4571, Ad4-Env145NFL, 5 x 108 viral particles (vp) | National Institute of Allergy and Infectious Diseases (NIAID) | HIV | 11/26 | 11/26 | | |
NCT06267872: A Clinical Trial in Adult Participants Without HIV and in Overall Good Health to Evaluate the Safety and Immunogenicity of CD4BS CH505M5 Pr-NP1 Followed by CH505 TF chTrimer Boost Both Adjuvanted With Either Lipid Nanoparticles (LNPs) or 3M-052-AF + Alum |
|
|
| Not yet recruiting | 1 | 42 | US, RoW | CD4BS CH505M5 Pr-NP1, CH505TF chTrimer, 3M-052-AF (labeled as AP 60-702), Aluminum Hydroxide Suspension (Alum), Alhydrogel, ACU-026-001-1 (labeled as empty LNP) | National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Department of Health and Human Services, Duke University, Access to Advanced Health Institute (AAHI) | HIV | 12/25 | 09/26 | | |
NCT04340596: Safety, Tolerability, and Efficacy of IL-15 Superagonist (N-803) With and Without Combination Broadly Neutralizing Antibodies to Induce HIV-1 Control During Analytic Treatment Interruption |
|
|
| Recruiting | 1 | 46 | US | N-803 (IL-15 Superagonist), VRC07-523LS, 10-1074 | National Institute of Allergy and Infectious Diseases (NIAID), Rockefeller University, ImmunityBio, Inc. | HIV Infection | 06/26 | 12/26 | | |
| Warren, Shannon Shay |
| Recruiting | 3 | 2000 | US | BCG (Tokyo 172) vaccine, Placebo, sodium glutamate | Henry M. Jackson Foundation for the Advancement of Military Medicine, United States Department of Defense, Uniformed Services University of the Health Sciences | Tuberculosis Infection | 09/27 | 09/27 | | |
| Spaulding, Savanna |
| Recruiting | 3 | 2000 | US | BCG (Tokyo 172) vaccine, Placebo, sodium glutamate | Henry M. Jackson Foundation for the Advancement of Military Medicine, United States Department of Defense, Uniformed Services University of the Health Sciences | Tuberculosis Infection | 09/27 | 09/27 | | |
| Spriggins, Kristen |
| Recruiting | 3 | 2000 | US | BCG (Tokyo 172) vaccine, Placebo, sodium glutamate | Henry M. Jackson Foundation for the Advancement of Military Medicine, United States Department of Defense, Uniformed Services University of the Health Sciences | Tuberculosis Infection | 09/27 | 09/27 | | |
| Tingle, William |
| Recruiting | 3 | 2000 | US | BCG (Tokyo 172) vaccine, Placebo, sodium glutamate | Henry M. Jackson Foundation for the Advancement of Military Medicine, United States Department of Defense, Uniformed Services University of the Health Sciences | Tuberculosis Infection | 09/27 | 09/27 | | |
| Simmons, Kimberly |
| Recruiting | 3 | 2000 | US | BCG (Tokyo 172) vaccine, Placebo, sodium glutamate | Henry M. Jackson Foundation for the Advancement of Military Medicine, United States Department of Defense, Uniformed Services University of the Health Sciences | Tuberculosis Infection | 09/27 | 09/27 | | |
| Active, not recruiting | 2 | 101 | US, RoW | Antithymocyte Globulin, Thymoglobulin, Placebo (for ATG) | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Diabetes Mellitus, Type 1 | 12/28 | 12/29 | | |
